Journal of Nuclear Medicine

Title Publication Date Language Citations
From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors2009/04/29English2,500
Partial-Volume Effect in PET Tumor Imaging2007/06/01English1,043
68Ga-FAPI PET/CT: Tracer Uptake in 28 Different Kinds of Cancer2019/04/06English793
Evaluation of Hybrid 68Ga-PSMA Ligand PET/CT in 248 Patients with Biochemical Recurrence After Radical Prostatectomy2015/03/19English771
Recommendations on the Use of 18F-FDG PET in Oncology2008/02/20English740
68Ga-DOTA-Tyr3-Octreotide PET in Neuroendocrine Tumors: Comparison with Somatostatin Receptor Scintigraphy and CT2007/04/01English652
225Ac-PSMA-617 for PSMA-Targeted α-Radiation Therapy of Metastatic Castration-Resistant Prostate Cancer2016/07/07English628
Introduction to Radiomics2020/02/14English624
Performance Measurements of the Siemens mMR Integrated Whole-Body PET/MR Scanner2011/11/11English612
Standards for PET Image Acquisition and Quantitative Data Analysis2009/04/20English592
German Multicenter Study Investigating177Lu-PSMA-617 Radioligand Therapy in Advanced Prostate Cancer Patients2016/10/20English575
Tissue Classification as a Potential Approach for Attenuation Correction in Whole-Body PET/MRI: Evaluation with PET/CT Data2009/03/16English548
MIRD Pamphlet No. 21: A Generalized Schema for Radiopharmaceutical Dosimetry—Standardization of Nomenclature2009/03/01English530
Intratumor Heterogeneity Characterized by Textural Features on Baseline 18F-FDG PET Images Predicts Response to Concomitant Radiochemotherapy in Esophageal Cancer2011/02/14English524
In Vivo Imaging of Amyloid Deposition in Alzheimer Disease Using the Radioligand 18F-AV-45 (Flobetapir F 18)2010/05/25English495
Development of Quinoline-Based Theranostic Ligands for the Targeting of Fibroblast Activation Protein2018/04/06English486
Multicenter Standardized 18F-FDG PET Diagnosis of Mild Cognitive Impairment, Alzheimer's Disease, and Other Dementias2008/02/20English444
Prospective Comparison of 18F-Fluoromethylcholine Versus 68Ga-PSMA PET/CT in Prostate Cancer Patients Who Have Rising PSA After Curative Treatment and Are Being Considered for Targeted Therapy2015/06/25English440
Tumor pH and Its Measurement2010/07/21English434
Causes and Consequences of Increased Glucose Metabolism of Cancers2008/06/01English428
68Ga-FAPI PET/CT: Biodistribution and Preliminary Dosimetry Estimate of 2 DOTA-Containing FAP-Targeting Agents in Patients with Various Cancers2018/08/02English426
A Tumor-Imaging Method Targeting Cancer-Associated Fibroblasts2018/04/06English418
PSMA-Targeted Radionuclide Therapy of Metastatic Castration-Resistant Prostate Cancer with 177Lu-Labeled PSMA-6172016/03/16English408
First Human Imaging Studies with the EXPLORER Total-Body PET Scanner*2019/02/07English402
Total-Body PET: Maximizing Sensitivity to Create New Opportunities for Clinical Research and Patient Care2017/09/21English401
Preclinical Evaluation of a Tailor-Made DOTA-Conjugated PSMA Inhibitor with Optimized Linker Moiety for Imaging and Endoradiotherapy of Prostate Cancer2015/04/16English398
Neuroinflammation in Schizophrenia-Related Psychosis: A PET Study2009/10/16English391
EANM/SNMMI Guideline for18F-FDG Use in Inflammation and Infection2013/01/28English387
68Ga- and 177Lu-Labeled PSMA I&T: Optimization of a PSMA-Targeted Theranostic Concept and First Proof-of-Concept Human Studies2015/06/18English381
First Clinical Experience with Integrated Whole-Body PET/MR: Comparison to PET/CT in Patients with Oncologic Diagnoses2012/04/25English379